European Journal of Rheumatology
Review Article

Resveratrol in Rheumatological Diseases: A Systematic Review

1.

Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil

2.

Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Ariel University, Ariel, Israel

Eur J Rheumatol 2023; 10: 163-168
DOI: 10.5152/eurjrheum.2023.23064
Read: 1056 Downloads: 425 Published: 20 October 2023

Resveratrol is an antioxidant with anti-inflammatory and cell-protective properties. The aim of our article is to review the use of resveratrol in rheumatic diseases. PubMed/Medline, Embase, and Scielo were screened for articles on resveratrol and rheumatic diseases in the period between of January 1966 and March 2023. Five articles were depicted, including 481 patients. The included diseases were osteoarthritis (n=3), rheumatoid arthritis (n=1), and Takayasu arteritis (n=1). The age varied from 32 to 58.2 years, and the female gender ranged from 62% to 74% in the studies. Disease duration ranged from 3.5 ± 3.2 to 9.4 ± 5.8 years. The resveratrol dosage went from 250 mg to 1000 mg/day. All those articles demonstrated improvements in the diverse rheumatic diseases, including pain intensity, function, disease activity (DAS 28), swelling joints, and reduced inflammation markers (erythrocyte sedimentation rate, C-reactive protein, interleukinIL-1, IL-6, and tumor necrosis factor). No side effects were detected in all studies. In conclusion, resveratrol seems to be a safe therapy for various rheumatic diseases, although the evidence is very limited. The improved subjective and objective complaints and laboratory parameters are promising. However, there is a need to reconfirm, reproduce, and investigate the topic in more extensive, well-controlled, double-blind, cross-over studies.

Cite this article as: Freire de Carvalho J, Lerner A. Resveratrol in rheumatological diseases: A systematic review. Eur J Rheumatol. 2023;10(4):163-168.

Files
EISSN 2148-4279